Vaxart, Inc.
NASDAQ:VXRT · NASDAQ Capital Market
-$0.01 today
Vol 0.35M · Avg 0.44M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
18.6%
avg -80.3%
ROIC
17.2%
avg -104.0%
ROA
8.8%
avg -66.3%
Analysis
ROE is currently the strongest return metric at 18.6% versus its period average of -80.3%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Steven Lo | President, Chief Executive Officer & Director | $1.07M | — | 59 | $2.49M | 1.03% |
James F. Cummings | Chief Medical Officer | $744,272.00 | — | 60 | $157,400.00 | 0.07% |
Sean N. Tucker | Senior Vice President & Chief Scientific Officer | $657,022.00 | — | 58 | $882,811.00 | 0.36% |
Shaily Jaini Garg | Senior Vice President of Clinical Development & Project Management | — | — | — | — | — |
Rajesh Kapoor | Senior Vice President of Quality | — | — | — | — | — |
Edward Berg | Senior Vice President & General Counsel | — | — | 62 | $755,368.00 | 0.31% |
Jeroen Grasman | Chief Financial Officer, Principal Accounting Officer & Principal Financial Officer | — | — | 56 | $545,605.00 | 0.23% |
Laurie Hastings | Senior Vice President of Human Resources | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
12
$96,620.24
Sells
0
$0.00
Net Sentiment
+$96,620.24
Net buying
Most Active
Finney Kevin
6 transactions
1–10 of 12
Analysis
Insiders reported 12 buys worth $96,620.24 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $96,620.24. Finney Kevin was the most active insider with 6 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -34.8% | +22.1% (14yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at -34.8% over three years. Forward estimates point to Revenue at +22.1% (14yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Relmada Therapeutics, Inc.
NASDAQ:RLMD
$487.67M
Unicycive Therapeutics, Inc.
NASDAQ:UNCY
$155.81M
Immunic, Inc.
NASDAQ:IMUX
$136.78M
Repare Therapeutics Inc.
RPTX
$114.24M
Fortress Biotech, Inc.
NASDAQ:FBIO
$92.02M
CAMP4 Therapeutics Corporation
NASDAQ:CAMP
$89.00M
PMV Pharmaceuticals, Inc.
NASDAQ:PMVP
$59.20M
Cibus, Inc.
NASDAQ:CBUS
$55.95M
TScan Therapeutics, Inc.
NASDAQ:TCRX
$55.71M
Acrivon Therapeutics, Inc. Common Stock
ACRV
$46.70M
Who manages VXRT?
Vaxart, Inc. (VXRT) lists 8 active executives. The top listed executive is Sean N. Tucker, Senior Vice President & Chief Scientific Officer.
Are VXRT insiders buying or selling?
Recent insider activity shows net buying of $18.13M.
Explore More
Continue the stock analysis
Jump to another research area for this company.